Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558316 | 0.86 | PTGS1 (0.64) | KMT2AMAOAMAOBPTGS1GSTP1 | |
| SCHEMBL7951909 | 0.81 | CYP2D6 (0.60) | KMT2APTGS1 | |
| SCHEMBL1419894 | 0.81 | PDE10A (0.59) | — | |
| SCHEMBL1957932 | 0.79 | F2 (0.62) | KMT2AMAOAMAOBPTGS1GSTP1 | |
| SCHEMBL9619055 | 0.79 | LMNA (0.53) | MAOAMAOBPTGS1GSTP1PTGS2 | |
| SCHEMBL1557809 | 0.77 | PTGS2 (0.62) | KMT2APTGS1PTGS2 | |
| SCHEMBL8770409 | 0.76 | MAOB (0.52) | KMT2AMAOAMAOBPTGS1 | |
| SCHEMBL2686651 | 0.75 | MAOB (0.63) | MAOAMAOBGSTP1 | |
| SCHEMBL298353 | 0.74 | GSTP1 (0.44) | KMT2AMAOBGSTP1F2PRMT5 | |
| SCHEMBL286490 | 0.74 | GSTP1 (0.44) | KMT2AMAOBGSTP1F2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-12-03 | — | — | US | disclosed |
| US-20140038965-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8481534-B2 | 5- and 6-membered heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2011-07-28 | — | — | US | disclosed |
| EP-2303863-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009158473-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | PDE7A, ACHE, PDE5A | KMT2A 2855/4885MAOA 29/4885MAOB 36/4885 |
| US-20140038965-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | PDE7A, ACHE, PDE5A | KMT2A 2855/4885MAOA 29/4885MAOB 36/4885 |
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ACHE, PDE7A, PDE5A | KMT2A 2900/4885MAOA 27/4885MAOB 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.